Fly News Breaks for February 11, 2020
Feb 11, 2020 | 12:05 EDT
The FDA lifted the clinical trial hold on Marker Therapeutics' acute myeloid leukemia program, allowing the company to devise a clearer path forward to initiate a phase II trial to evaluate its MultiTAA T-cells in post-transplant setting, Roth Capital analyst Tony Butler tells investors in a research note. A partial hold exists which is expected to be in place until the final analysis of data from the safety lead-in portion of the trial is available in Q2 of 2020, adds the analyst. Butler says that while Marker now has a path forward, "some uncertainties still remain." He maintains a Buy rating on the shares with an $8 price target.
News For MRKR From the Last 2 Days
There are no results for your query MRKR